Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
The impact of cotrimoxazole prophylaxis in HIV-infected children on antimicrobial resistance gene carriage in the fecal microbiome.
FY 2018-19
Summary
The immune system is the body’s defence against invading pathogens. Human immunodeficiency virus (HIV) interferes with the normal functioning of the immune system, thereby increasing the chances of infection. Antibiotics have primarily been used to treat and prevent bacterial infections; but with continued usage these organisms have developed antibiotic resistance, rendering some infections untreatable. The World Health Organization (WHO) recommends that the antibiotic cotrimoxazole (CTX) be given, along with antiretroviral therapy, to any child born with or exposed to HIV, to help prevent serious infections and death. Antiretroviral Research for Watoto (ARROW) is a clinical trial of Ugandan and Zimbabwean HIV-infected children, aged 3 months to 17 years, designed in part to investigate whether stopping versus continuing CTX would benefit the child health over the long term. ARROW found that continuing CTX did further reduce infections and hospitalizations. However, long term use of CTX might lead to big increases in carriage of or infection with highly drug resistant bacteria (so-called ‘superbugs’). My research project is to understand the extent of CTX resistance in these children by analyzing fecal microbes using DNA sequencing methods to determine if stopping CTX prophylaxis reduced the quantity and diversity of resistance genes carried by the gut bacteria of these HIV-infected children. Results of this research will inform future WHO decisions regarding the trade-off between the use of CTX to prevent infections and further increases in multi-drug-resistant bacteria.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
406327
Name
Francis Abelanjo Freddy
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The impact of cotrimoxazole prophylaxis in HIV-infected children on antimicrobial resistance gene carriage in the fecal microbiome.
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antibiotic Prophylaxis; Antimicrobial Resistance; Antimicrobial Stewardship; Co-Resistance; Endemic Resistance; Gut Flora; Hiv Therapy; Microbiome; Multi-Drug-Resistant Organisms; Risk Of Resistance
Abstract
The immune system is the body’s defence against invading pathogens. Human immunodeficiency virus (HIV) interferes with the normal functioning of the immune system, thereby increasing the chances of infection. Antibiotics have primarily been used to treat and prevent bacterial infections; but with continued usage these organisms have developed antibiotic resistance, rendering some infections untreatable. The World Health Organization (WHO) recommends that the antibiotic cotrimoxazole (CTX) be given, along with antiretroviral therapy, to any child born with or exposed to HIV, to help prevent serious infections and death. Antiretroviral Research for Watoto (ARROW) is a clinical trial of Ugandan and Zimbabwean HIV-infected children, aged 3 months to 17 years, designed in part to investigate whether stopping versus continuing CTX would benefit the child health over the long term. ARROW found that continuing CTX did further reduce infections and hospitalizations. However, long term use of CTX might lead to big increases in carriage of or infection with highly drug resistant bacteria (so-called ‘superbugs’). My research project is to understand the extent of CTX resistance in these children by analyzing fecal microbes using DNA sequencing methods to determine if stopping CTX prophylaxis reduced the quantity and diversity of resistance genes carried by the gut bacteria of these HIV-infected children. Results of this research will inform future WHO decisions regarding the trade-off between the use of CTX to prevent infections and further increases in multi-drug-resistant bacteria.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Francis, Abelanjo Freddy
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~